From the Journals

E-cigarette usage has changed

Publish date: May 15, 2018
By
Richard Franki

 

FROM JAMA

Adults were more likely to try e-cigarettes in 2016 than they were in 2014, but they were less likely to use them regularly, according to a study published online on May 15 by JAMA.

The prevalence of ever use of e-cigarettes among adults aged 18 years and older rose significantly from 12.6% in 2014 to 15.3% in 2016, while the prevalence of current use (defined as use every day or some days) decreased significantly from 3.7% to 3.2% over that same period, suggesting “that some individuals are trying but not continuing use of e-cigarettes,” Wei Bao, MD, PhD, and his associates said in a research letter.

Prevalence of e-cigarette use in adults, 2014-2016
The patterns of increased ever use and decreased current use held for most age-, gender-, and race/ethnicity-related subgroups, although “current use of e-cigarettes declined among current smokers but increased among former smokers. This pattern may reflect e-cigarette use as adults are transitioning from current to former smokers, but further investigation is warranted,” wrote Dr. Bao of the University of Iowa College of Public Health, Iowa City, and his associates.

None of the investigators reported any conflicts of interest.

SOURCE: Bao W et al. JAMA. 2018 May 15;319(19):2039-41.

Recommended Reading

Nivolumab plus ipilimumab boosts PFS in advanced NSCLC with high tumor mutational burden
MDedge Hematology and Oncology
MDedge Daily News: Which diabetes drug boosts survival best?
MDedge Hematology and Oncology
FDA approves osimertinib for first-line advanced EGFR-mutated NSCLC
MDedge Hematology and Oncology
Screening tool IDs older NSCLC patients suitable for SBRT
MDedge Hematology and Oncology
ALUR: Alectinib topped chemo in pretreated ALK-positive NSCLC
MDedge Hematology and Oncology
Isolated ocular metastases from lung cancer
MDedge Hematology and Oncology
Bevacizumab-awwb becomes first biosimilar approved for cancer treatment
MDedge Hematology and Oncology
Qualitative assessment of organizational barriers to optimal lung cancer care in a community hospital setting in the United States
MDedge Hematology and Oncology
Checkpoint inhibitors get to patients quickly
MDedge Hematology and Oncology
Delay of NSCLC surgery can lead to worse prognosis
MDedge Hematology and Oncology